Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Horizon Therapeutics Pub L's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Horizon Therapeutics Pub L's position in the market.
Horizon Therapeutics and the Cubs have partnered for a Legacy Partnership, launching a Cubs STEAM Program aimed at engaging middle and high school students in science through baseball. The program will feature a citywide science camp and fair, facilitating hands-on learning about the intersection of science and baseball. Additionally, the partnership includes an event during Spring Training 2022 to raise awareness about rare diseases. Horizon's initiative seeks to nurture future science leaders while highlighting the challenges faced by those with rare diseases.
Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first patient in the FORWARD trial, assessing a new monthly dosing of 16 mg KRYSTEXXA with methotrexate for treating uncontrolled gout. This trial aims to lower treatment frequency, potentially enhancing patient experience. The primary endpoint measures responder rates in maintaining low serum uric acid levels. With 30 participants targeted, the protocol remains unapproved by health authorities. Safety concerns exist regarding anaphylaxis and infusion reactions during treatment.
Horizon Therapeutics plc (Nasdaq: HZNP) announced that Mitsubishi Tanabe Pharma Corporation received approval for UPLIZNA from the Japanese Ministry of Health. This drug is aimed at preventing relapses in neuromyelitis optica spectrum disorder (NMOSD). MHPC holds rights for UPLIZNA's development in several Asian markets. Horizon stands to gain milestone payments and sales-related revenues. Tim Walbert emphasized the approval's significance for NMOSD patients and Horizon's commitment to expanding treatment options globally.
Horizon Therapeutics plc (Nasdaq: HZNP) has launched The Horizon Prize, an annual global innovation challenge in partnership with MIT Solve, aimed at enhancing diagnosis and care for individuals with rare diseases. Each year, the challenge will focus on a unique question to stimulate innovative solutions. This year’s inquiry targets utilizing technology to expedite accurate care for rare disease patients. With an annual funding pool of up to $150,000 for two teams, the initiative seeks solutions leveraging big data, patient advocacy, and collaboration among stakeholders in the healthcare ecosystem.
Horizon Therapeutics (Nasdaq: HZNP) has acquired Viela Bio (Nasdaq: VIE) for $53.00 per share, a transaction valued at over $3 billion. This acquisition enhances Horizon's commercial portfolio in rare diseases, particularly with UPLIZNA, the first FDA-approved treatment for neuromyelitis optica spectrum disorder. The deal will strengthen Horizon's R&D capabilities and add a mid-stage biologics pipeline targeting autoimmune diseases. However, Horizon expects a $140 million decrease in adjusted EBITDA for 2021 due to increased R&D expenditures.
Summary not available.
Summary not available.
Horizon Therapeutics plc (Nasdaq: HZNP) will participate in the Cowen and Company 41st Annual Health Care Conference (Virtual) on March 2, 2021, at 1:30 p.m. ET. The event will be webcast live, and the link can be found on Horizon's website. A replay of the presentation will be available afterward. Horizon focuses on developing therapeutics for patients with rare and rheumatic diseases, aiming to transform lives through science and compassion.
Horizon Therapeutics plc (Nasdaq: HZNP) reported record financial results for Q4 and the full year 2020, highlighting a 105% increase in Q4 net sales to $745.3 million and 69% growth in FY 2020 to $2.2 billion. The company announced positive guidance for 2021, projecting net sales between $2.70 billion to $2.80 billion. CEO Tim Walbert emphasized the successful launch of TEPEZZA and a definitive agreement to acquire Viela Bio, adding to its robust pipeline. However, net income saw a significant decline of 68% in Q4.
Summary not available.